Sugi Predict

Sugi Predict / Compounds / SCHEMBL3014948

SCHEMBL3014948

SCHEMBL3014948

CC(C)(C)[Si](C)(C)OCc1nccs1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 2/20 0.40
▸ CHRM1 P11229 2/20 0.40
▸ CHRM3 P20309 2/20 0.40
▸ FDPS P14324 1/20 0.35
▸ FBP1 P09467 1/20 0.34
▸ CYP2D6 P10635 1/20 0.33
▸ SLC6A3 Q01959 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ CYP3A4 P08684 5/20 0.32
▸ ACACB O00763 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ PKM P14618 1/20 0.32
▸ TRPM8 Q7Z2W7 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL737429 0.85 DUT (0.39) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL30561243 0.82 LTA4H (0.34) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL38661401 0.82 FDPS (0.33) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL38663161 0.82 FDPS (0.33) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL736293 0.80 DUT (0.37) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL13230280 0.77 CHRM2 (0.41) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL7979718 0.76 FDPS (0.42) FDPSSLC6A3ACACBALDH1A1PKM
SCHEMBL21854492 0.76 SLC6A3 (0.38) CHRM2CHRM1CHRM3SLC6A3CYP3A4
SCHEMBL25258844 0.74 CHRM2 (0.40) CHRM2CHRM1CHRM3FDPSFBP1
SCHEMBL777769 0.74 FDPS (0.40) CHRM2CHRM1CHRM3FDPSFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598931-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2025-08-13 — — EP disclosed
WO-2024076300-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2024-04-11 — — WO disclosed
US-20240059698-A1 HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES ACCUTAR BIOTECHNOLOGY INC. (US) 2024-02-22 — — US disclosed
WO-2024026056-A2 HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES ACCUTAR BIOTECHNOLOGY, INC. (US) 2024-02-01 — — WO disclosed
US-20230058961-A1 SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV NATIONAL INSTITUTES OF HEALTH 2023-02-23 — — US disclosed
WO-2022155941-A1 CDK2 INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2022-07-28 — — WO disclosed
WO-2022155941-A1 CDK2 INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2022-07-28 — — WO disclosed
CN-114727987-A Substituted heterocyclic compounds having HIV therapeutic activity 纽约血库公司 2022-07-08 — — CN disclosed
US-9227971-B2 Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 — — US disclosed
US-9227971-B2 Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 — — US disclosed
US-20120322791-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-12-20 — — US disclosed
US-20120322791-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-12-20 — — US disclosed
US-20100197678-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-05 — — US disclosed
US-20100197678-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-05 — — US disclosed
EP-2102170-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2009-09-23 — — EP disclosed
WO-2008070507-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-12 — — WO disclosed
US-5681840-A ANTIDOPAMINERGIC AGENTS ZENECA LIMITED (GB) 1997-10-28 — — US disclosed
EP-0533344-B1 Methanoanthracenes as dopamine antagonists ZENECA LTD (GB) 1996-10-16 — — EP disclosed
US-5512575-A ANTISEROTONINE AGENT ZENECA LIMITED (GB) 1996-04-30 — — US disclosed
EP-0533344-A1 Methanoanthracenes as dopamine antagonists ZENECA LIMITED (GB) 1993-03-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230058961-A1 SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV CD4, NFATC1, PAICS CHRM2 4807/4885CHRM1 4790/4885CHRM3 4787/4885
US-20100197678-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof NR3C1, NR3C2, MC2R CHRM2 410/4885CHRM1 361/4885CHRM3 340/4885
US-20120322791-A1 PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS MTOR, RICTOR, RPS6KA5 CHRM2 4537/4885CHRM1 4308/4885CHRM3 4828/4885
US-20240059698-A1 HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES EGFR, ERBB2, ERBB3 CHRM2 4846/4885CHRM1 4865/4885CHRM3 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.